Makers of Amplimune, USDA-approved immunotherapy for scours.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the U.S.A. (made in Athens, GA). One formulation has been developed as an anticancer therapy in dogs and horses. Other formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease. The cattle product - Amplimune(R) - reduces the clinical signs and mortality associated with E. coli K99 diarrhea in neonatal calves. The product is a USDA-approved emulsion of MCWF that, when administered to the animal, enhances innate immunity to fight bacterial infections without the use of antibiotics. Amplimune is OMRI Listed in the U.S.A. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform. For more information about the Company, visit https://www.NovaVive.ca or email info@NovaVive.ca.
Brands: Amplimune is a USDA-approved immunotherapy to treat E. coli K99 diarrhea in newborn calves. It stimulates the immune system to fight infection without the use of antibiotics and it is OMRI Listed.